We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Selective binge

17 December 2015 By Neil Unmack

The UK pharma group has spent $4 bln on a stake in cancer specialist Acerta. Its acquisitions this quarter now total more than $7 bln. The dealmaking reflects new-drug pipeline challenges and sector-wide price pressure. Astra is ratcheting up the risk, but the approach looks sound.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)